Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/007461IMMUNOMODULATOR
WO 13.01.2022
Int.Class C07D 409/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Appl.No PCT/CN2021/087548 Applicant HITGEN INC. Inventor LI, Jin
Disclosed is an immunomodulator, and the present invention specifically relates to a compound for inhibiting IL-17A and an application of the compound serving as the immunomodulator in the preparation of a drug. Disclosed is an application of a compound represented by formula I or a stereoisomer thereof in preparing a drug for inhibiting IL-17A, and a new choice for clinically screening and/or preparing a drug for treating diseases related to IL-17A activity is provided.
2.WO/2022/007866FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF
WO 13.01.2022
Int.Class C07D 233/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
233Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
54having two double bonds between ring members or between ring members and non-ring members
66with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
72Two oxygen atoms, e.g. hydantoin
76with substituted hydrocarbon radicals attached to the third ring carbon atom
Appl.No PCT/CN2021/105088 Applicant SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Inventor WU, Junjun
A fused tricyclic derivative relating to the technical field of chemical drugs, a preparation method therefor, and a pharmaceutical application thereof. The fused tricyclic derivative is an inhibitor of aggrecanase-2 (ADAMTS-5). Also provided are a pharmaceutical composition comprising the compound and a use of the compound in the preparation of a drug for treating diseases such as osteoarthritis.
3.WO/2022/009036SYNTHESIS OF FAVIPIRAVIR
WO 13.01.2022
Int.Class A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Appl.No PCT/IB2021/055912 Applicant OPTIMUS DRUGS (P) LTD Inventor DESI REDDY, Srinivas Reddy
The present invention relates to 6-Fluoro-3-hydroxypyrazine-2-carbonitrile ammonia salt and to an improved and commercially viable process for preparation of Favipiravir using 6-fluoro-3-hydroxypyrazine-2-carbonitrile ammonia salt.
4.WO/2022/009651COMPOUND, LIGHT-EMITTING MATERIAL, AND LIGHT-EMITTING DEVICE
WO 13.01.2022
Int.Class C07D 491/048
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
044with only one oxygen atom as ring hetero atom in the oxygen-containing ring
048the oxygen-containing ring being five-membered
Appl.No PCT/JP2021/023285 Applicant KYULUX, INC. Inventor FUJISAWA Kaori
A compound represented by general formula below is useful as a light-emitting material. Ar is a hydrogen atom, an aromatic hydrocarbocyclic group, or a nitrogen atom-containing aromatic heterocyclic group; 1-3 of R1 to R4 are carbazole-9-yl groups condensed with a benzofuran ring; 1-3 of R1 to R4 are other donor groups; and the rest are hydrogen atoms.
5.WO/2022/010386USE OF COFACTOR FO AND ANALOGUES THEREOF AS A BIOLUMINESCENCE REACTION COMPONENT
WO 13.01.2022
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/RU2021/050207 Applicant YAMPOL'SKIY, Il'ya Viktorovich Inventor YAMPOL'SKIY, Il'ya Viktorovich
Components of bioluminescent systems are widely used reagents for a large number of assays, including diagnostic systems, quality control systems, drug trial systems and the like. The present group of inventions discloses components of the bioluminescent system of Henlea petushkovi and Henlea rodionovae (Henlea sp.) worms, in particular bioluminescence cofactor (activator) molecules. The present group of inventions further discloses a method for identifying luciferase in biological samples using bioluminescence cofactor (activator) molecules from Henlea petushkovi and Henlea rodionovae (Henlea sp.) worms, and a method for detecting bioluminescence in a biological sample.
6.WO/2022/011091TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES
WO 13.01.2022
Int.Class A61K 31/5025
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
5025ortho- or peri-condensed with heterocyclic ring systems
Appl.No PCT/US2021/040810 Applicant USHER III INITIATIVE, INC. Inventor FARHAN, Mahdi
The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.
7.WO/2022/011391SALTS AND FORMS OF A WEE1 INHIBITOR
WO 13.01.2022
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/US2021/070851 Applicant RECURIUM IP HOLDINGS, LLC Inventor HOPKINS, Chad, Daniel
The salt, such as adipate salt Form A, and freebase forms of Compound A are WEE1 inhibitors. Such salts and/or forms and freebase forms, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
8.20220011668SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN
US 13.01.2022
Int.Class G03F 7/004
GPHYSICS
03PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
FPHOTOMECHANICAL PRODUCTION OF TEXTURED OR PATTERNED SURFACES, e.g. FOR PRINTING, FOR PROCESSING OF SEMICONDUCTOR DEVICES; MATERIALS THEREFOR; ORIGINALS THEREFOR; APPARATUS SPECIALLY ADAPTED THEREFOR
7Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
004Photosensitive materials
Appl.No 17360366 Applicant SUMITOMO CHEMICAL COMPANY, LIMITED Inventor Katsuhiro KOMURO

A salt represented by formula (I), an acid generator and a resist composition:

embedded image

wherein R1, R2 and R3 each represent a hydroxy group, —O—R10, —O—CO—O—R10, —O-L1-CO—O—R10; R4, R5, R6, R7, R8 and R9 each represent a halogen atom, a hydroxy group, etc.; L1 represents an alkanediyl group; R10 represents an acid-labile group; X1, X2 and X3 each represent an oxygen atom or a sulfur atom; m1 and m7 represent an integer of 0 to 5, m2 to m6 and m8, m9 represent an integer of 0 to 4, in which 0≤m1+m7≤5, 0≤m2+m8≤4, 0≤m3+m9≤4, and at least one of m1, m2 and m3 represents an integer of 1 or more; X4 represents a single bond, —CH2—, —O—, —S—, etc.; and AI represents an organic anion.

9.WO/2022/006667DIAGNOSIS AND TREATMENT OF CHRONIC DIABETIC COMPLICATIONS USING LONG NON-CODING RNAS AS TARGETS
WO 13.01.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/CA2021/050924 Applicant THE UNIVERSITY OF WESTERN ONTARIO Inventor CHAKRABARTI, Subrata
Method of identifying a subject as having an increased likelihood of progressing to end-organ damage due to diabetes comprising comparing the amount of a lncRNA in a sample from the subject with a reference value, and if the amount of the lncRNA in the sample is increased relative to the reference value, identifying the subject as having an increased probability of progressing to end-organ damage due to diabetes. The lncRNA is one or more of HOTAIR, H19, WISPER, ZFAS1, HULC, ANRIL, MALAT1, MIAT, and MEG3. Also methods of treating chronic diabetic complications and other conditions comprising administering a HOTAIR inhibitor.
10.WO/2022/007372PYRIMIDINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION
WO 13.01.2022
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/CN2021/000132 Applicant INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES Inventor SUN, Lianqi
Provided are a pyrimidinone derivative, and a preparation method therefor and the use thereof against Mycobacterium tuberculosis infection. The structure of the pyrimidinone derivative is represented by formula I. Experiments prove that the pyrimidinone derivative has obvious anti-Mycobacterium tuberculosis activity and is particularly suitable for preparing a drug for preventing and/or treating related diseases caused by Mycobacterium tuberculosis.